Quantcast

Latest gastrointestinal stromal tumor Stories

2009-07-29 10:21:34

A research article to be published on July 21, 2009 in the World Journal of Gastroenterology addresses this question. This research led by Professor Kim and his colleagues in Pusan National University, South Korea. They evaluated the EUS features of gastric GISTs in comparison with gastric leiomyomas, and tried to determine the EUS features that could predict the malignant potential of gastric GISTs according to the histological risk classification.In their study, to differentiate GISTs from...

2009-07-16 16:42:57

Survival rate racial differences for gastrointestinal tumors are narrowing between African-Americans and whites, U.S. researchers said. The study, published in the Journal of the American College of Surgeons, found in the case of a rare cancer that begins in the wall of the gastrointestinal tract known as a gastrointestinal stromal tumor, the 30-day surgical mortality rate which was higher in African-Americans prior to the year 2000 has become equivalent in the last 10 years. Over the last...

2009-07-14 10:45:00

After years of inequality, survival rates now equivalent to those of CaucasiansNew research published in the July issue of the Journal of the American College of Surgeons reveals that African Americans with gastrointestinal stromal tumors (GIST), a rare cancer that begins in the wall of the gastrointestinal tract, now have survival rates equivalent to those of Caucasians. Prior to 2000, African Americans were more likely to develop GIST and less likely to undergo surgical treatment for this...

2009-06-01 08:02:00

Company Expands Diagnostic Services with K9 Clone DOG-1 Immunohistochemical and H. pylori Monoclonal Antibody Tests LAKEWOOD, N.J., June 1 /PRNewswire/ -- PLUS Diagnostics, a leading U.S. anatomic pathology company offering a full range of multi-specialty services, announced today that it is the first national laboratory to offer a highly specialized test that definitively diagnoses the rare gastrointestinal stromal tumor ("GIST"). Known as the K9 clone DOG-1 immunohistochemical assay, the...

2009-05-19 06:00:00

Partner Keryx to present Phase 2 data on perifosine for multiple cancers QUEBEC CITY, May 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108, in prostate cancer, will be presented as a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be...

2009-05-18 07:29:00

Results Will be Reported from Phase 2 Studies Evaluating KRX-0401 in Advanced Renal Cell Carcinoma, Colorectal Cancer and Gastrointestinal Stromal Tumors (GIST) NEW YORK, May 18 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that four abstracts on KRX-0401 (Perifosine), the Company's Akt-inhibitor for cancer, were accepted for presentation during poster sessions taking place at the 45th Annual Meeting of the American Society of Clinical Oncology...

2009-05-15 09:34:27

Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.Lori Rink, PhD, a postdoctoral fellow in the laboratory of Andrew K. Godwin, PhD, at Fox Chase, presents their findings at the 2009 Annual Meeting of the American...

2009-05-08 00:00:00

FRIMLEY, England, May 8 /PRNewswire/ -- - Glivec(R) (imatinib) Now Approved in the UK for Post-Surgery Treatment of Patients With KIT (CD117)-Positive Gastrointestinal Stromal Tumours (GIST), who are at Significant Risk of the Cancer Returning After Surgery(1) - Use of Glivec(R) After Surgery Significantly Reduces Risk of Cancer Relapse(2) - If Untreated After Surgery, 50% of patients Will Experience Their Cancer Returning Within Two Years(3,4) Glivec(R) has been...

2009-03-18 17:37:00

- Estimated one-year, recurrence-free survival was 98% for Kit-positive GIST patients taking Gleevec vs. 83% for patients taking placebo(1) - Historically, one in two patients experienced recurrence of GIST(2) within a median of two years after surgery(3) - Gleevec is the only treatment in the US and Switzerland indicated to reduce risk of recurrence of GIST after surgery; regulatory review is underway in the EU(4) EAST HANOVER, N.J., March 18, 2009 /PRNewswire/ -- Data published today...

2009-01-15 06:34:50

Research published in Journal of the American College of Surgeons finds survival rate of nearly 80 percent New research published in the January issue of the Journal of the American College of Surgeons shows that laparoscopic removal of gastrointestinal stromal tumors (GISTs) is safe and effective, with a disease-free survival rate of nearly 80 percent after an average follow-up time of three and a-half years. GIST is a type of cancer arising from special cells in the wall of the...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related